| Yampa Valley Medical Center | |
|
15 Lash St Baggs WY 82321-5005 | |
| (307) 383-2008 | |
| Not Available |
| Full Name | Yampa Valley Medical Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 15 Lash St, Baggs, Wyoming |
| Authorized Official Name and Position | Christopher Daniel Rieber (UCHEALTH CFO) |
| Authorized Official Contact | 3073832008 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Yampa Valley Medical Center 2695 Rocky Mountain Ave Ste 150 Loveland CO 80538-9071 Ph: () - | Yampa Valley Medical Center 15 Lash St Baggs WY 82321-5005 Ph: (307) 383-2008 |
| NPI Number | 1841607074 |
|---|---|
| Provider Enumeration Date | 07/21/2014 |
| Last Update Date | 11/07/2023 |
| Medicare PECOS PAC ID | 5890685689 |
|---|---|
| Medicare Enrollment ID | O20150304000291 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841607074 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Provider Name | Jona Ely |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225174394 PECOS PAC ID: 0042488298 Enrollment ID: I20150415001173 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
| Provider Name | Crystal Laree Henderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952757247 PECOS PAC ID: 8426342569 Enrollment ID: I20160811001810 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
| Provider Name | Jonathan T Hamilton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1639159239 PECOS PAC ID: 7810978400 Enrollment ID: I20190628002499 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
| Provider Name | Scott Bissell Loomis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992977052 PECOS PAC ID: 7719122779 Enrollment ID: I20200904001536 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
| Provider Name | Kimberley Jean Paden-harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639445257 PECOS PAC ID: 6002071420 Enrollment ID: I20201026003111 |
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
News Archive
Diamond has announced that USA-based global biotechnology company Vertex Pharmaceuticals Incorporated is the first industrial user at the UK's world class new research facility, Diamond Light Source
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.
How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment - This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."
› Verified 3 days ago
Noyes Health Care Center Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 305 Whippoorwill St, Pob 307, Baggs, WY 82321 Phone: 307-383-7000 Fax: 307-383-7005 | |
Stagecoach Health Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 511 Osborne St., Baggs, WY 82321 Phone: 307-380-3058 |